Microsoft word - rimonabant 051108 eng final.doc

Press release Sanofi-aventis

Paris, November 5, 2008 - Sanofi-aventis announced today that it has decided to discontinue the
ongoing rimonabant clinical development program in all indications.
Today’s company decision has been taken in light of recent demands by certain national health
authorities. As a result the feasibility of the global clinical development program has been
compromised.

Sanofi-aventis will inform Health Care Professionals as of today. Persons currently enrolled in these
clinical trials should consult their clinical investigator to discuss their treatment.
This announcement does not change the Company’s guidance for 2008.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes
therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com.
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that are not historical facts. These statements include product
development, product potential projections and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future events, operations, products and services, and statements
regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,”
“believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the
expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether
and when to approve any drug, device or biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such
products candidates, the absence of guarantee that the products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the
public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year
ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to
update or revise any forward-looking information or statements.

Sanofi-aventis www.sanofi-aventis.com
Media Relations: Tel. : (+) 33 1 53 77 44 50 - E-mail : [email protected]
Investor Relations : Tel. : (+) 33 1 53 77 45 45 - E-mail : [email protected]

Source: http://sanoficanada.mediaroom.com/download/7D7C2FBB-16CD-4348-89BE-0BA5691E0710.pdf